↓ Skip to main content

Behavioral Neurobiology of Anxiety and Its Treatment

Overview of attention for book
Cover of 'Behavioral Neurobiology of Anxiety and Its Treatment'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Pharmacotherapy of Social Anxiety Disorder
  3. Altmetric Badge
    Chapter 2 Pharmacological treatment of generalized anxiety disorder.
  4. Altmetric Badge
    Chapter 3 Antidepressant Treatment in Anxiety Disorders
  5. Altmetric Badge
    Chapter 4 Anxiety disorders diagnosis: some history and controversies.
  6. Altmetric Badge
    Chapter 5 Functional neuroanatomy of anxiety: a neural circuit perspective.
  7. Altmetric Badge
    Chapter 6 Genetics
  8. Altmetric Badge
    Chapter 7 Neuroanatomy of Anxiety
  9. Altmetric Badge
    Chapter 8 The Pharmacology of Anxiety
  10. Altmetric Badge
    Chapter 9 Epidemiology of Anxiety Disorders
  11. Altmetric Badge
    Chapter 10 Pharmacological Enhancement of Behavioral Therapy: Focus on Posttraumatic Stress Disorder
  12. Altmetric Badge
    Chapter 11 Behavioral Correlates of Anxiety
  13. Altmetric Badge
    Chapter 12 Pharmacological Treatment of Obsessive-Compulsive Disorder
  14. Altmetric Badge
    Chapter 13 Stress and the Neuroendocrinology of Anxiety Disorders
  15. Altmetric Badge
    Chapter 14 Developing Small Molecule Nonpeptidergic Drugs for the Treatment of Anxiety Disorders: Is the Challenge Still Ahead?
  16. Altmetric Badge
    Chapter 15 Pharmacotherapy of Post-Traumatic Stress Disorder
  17. Altmetric Badge
    Chapter 16 Cannabinoids and anxiety.
  18. Altmetric Badge
    Chapter 17 Animal Models of Anxiety and Anxiolytic Drug Action
  19. Altmetric Badge
    Chapter 30 GABA A Receptor α2/α3 Subtype-Selective Modulators as Potential Nonsedating Anxiolytics
  20. Altmetric Badge
    Chapter 31 Genetic Approaches to Modeling Anxiety in Animals
  21. Altmetric Badge
    Chapter 32 Comorbidity in Anxiety Disorders
  22. Altmetric Badge
    Chapter 33 Challenging Anxiety: A Focus on the Specificity of Respiratory Symptoms
  23. Altmetric Badge
    Chapter 35 Pharmacologic Treatment of Panic Disorder
  24. Altmetric Badge
    Chapter 36 Metabotropic Glutamate Receptors: Their Therapeutic Potential in Anxiety
Attention for Chapter 2: Pharmacological treatment of generalized anxiety disorder.
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#6 of 103)
  • High Attention Score compared to outputs of the same age (87th percentile)

Mentioned by

blogs
1 blog

Readers on

mendeley
47 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Pharmacological treatment of generalized anxiety disorder.
Chapter number 2
Book title
Behavioral Neurobiology of Anxiety and Its Treatment
Published in
Current topics in behavioral neurosciences, February 2011
DOI 10.1007/7854_2009_2
Pubmed ID
Book ISBNs
978-3-64-202911-0, 978-3-64-202912-7
Authors

Baldwin DS, Ajel KI, Garner M, David S. Baldwin, Khalil I. Ajel, Matthew Garner

Abstract

Generalized anxiety disorder (GAD) is common in community and clinical settings. The individual and societal burden associated with GAD is substantial, but many of those who could benefit from treatment are not recognized or treated. Recent evidence-based guidelines for the pharmacological management of patients with GAD have recommended initial treatment with either a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI), on the basis of their proven efficacy and reasonable tolerability in randomized placebo-controlled trials. However, there is much room for improvement in both the efficacy and the tolerability of treatment. Response rates to first-line treatment can be disappointing and it is hard to predict reliably which patients will respond well and which will have only a limited treatment response. Many patients worry about becoming dependent on medication, a substantial proportion experience troublesome adverse effects, and these problems limit the effectiveness of pharmacological treatments in clinical practice. The relative lack of longitudinal studies of clinical outcomes in GAD, and the small number of placebo-controlled relapse prevention studies lead to uncertainty about the optimal duration of treatment after a satisfactory initial response. There have been few investigations of the further management of patients who have not responded to first-line treatment and there is a pressing need for further augmentation studies in patients who have not responded to an SSRI or SNRI, or to other initial pharmacological approaches. Future treatment guidelines for GAD will be influenced by emerging data for established and novel pharmacological approaches, and possibly through the more accurate identification of certain patient subgroups who are likely to respond preferentially to particular interventions.

Mendeley readers

The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 47 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 11 23%
Researcher 7 15%
Student > Master 6 13%
Student > Ph. D. Student 6 13%
Student > Postgraduate 4 9%
Other 9 19%
Unknown 4 9%
Readers by discipline Count As %
Medicine and Dentistry 22 47%
Psychology 12 26%
Agricultural and Biological Sciences 4 9%
Neuroscience 3 6%
Arts and Humanities 1 2%
Other 0 0%
Unknown 5 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 March 2011.
All research outputs
#327,792
of 3,632,408 outputs
Outputs from Current topics in behavioral neurosciences
#6
of 103 outputs
Outputs of similar age
#10,156
of 85,293 outputs
Outputs of similar age from Current topics in behavioral neurosciences
#1
of 2 outputs
Altmetric has tracked 3,632,408 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 103 research outputs from this source. They receive a mean Attention Score of 3.2. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 85,293 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them